Tags : Chronic Autoimmune Diseases


Eli Lilly Signs an Exclusive Worldwide License Agreement with ImmuNext

Shots:  ImmuNext to receive $40M upfront, $565M as development & commercialization milestones and royalties on sales of products. Lilly to get an exclusive WW licence to develop & commercialize novel immuno-therapies  Eli Lilly and ImmuNext plan to build a 3yrs. research collaboration supporting the development of preclinical targets for autoimmune diseases by regulating immune cell […]Read More